10-Q quarterly report · filed Nov 6, 2026

ARTIVION, INC. (AORT) Q3 2026 10-Q Quarterly Report

Short answer

ARTIVION, INC. (AORT) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $124M (up 9.2% year over year) with net income of −$8M.

Q3 2026 key financials · XBRL

Revenue
$124M
+9.2% YoY · −1.6% QoQ
Net income
−$8M
−221.9% YoY · +41.3% QoQ
Operating margin
2.4%
Gross margin
61.4%
EPS (diluted)
−$0.16
−214.3% YoY · +42.9% QoQ

Source: XBRL data from the ARTIVION, INC. (AORT) Q3 2026 10-Q on SEC EDGAR. USD.

ARTIVION, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $123.8M, up 9% YoY from $113.4M
  • Gross margin 61% vs 66% YoY, pressured by higher costs and unfavorable mix
  • Best performer: Other revenue $4.6M, up 93%; worst: Surgical sealants $18.9M, flat YoY
  • Cash $48.4M, operating cash flow $(4.7)M vs $20.3M YoY
  • Endospan acquisition used $116.7M; $150.0M term loan raised; PerClot manufacturing expected to end by year-end 2026

Risk Factors

  • Italian medical-device repayment exposure, approximately $2.3 million for 2019–2025, pending government assessment
  • Endospan acquisition completed May 18, 2026, adding NEXUS manufacturing concentration in Herzliya, Israel amid regional conflict
  • CryoValve SGPV reclassification risk, potential Class III designation could make continued processing commercially infeasible
  • FDA and other regulatory review delays, reduced federal staffing could delay clinical trials and product approvals
  • Variable-rate indebtedness, covenant breach could accelerate repayment and permit foreclosure on substantially all US assets

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ARTIVION, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.